StockData
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. (AARD) company profile

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.15−0.11 (-8.73%)

Close on Nov 17, 2026Market cap $25.17MP/E –Yield –

About Aardvark Therapeutics

Pharmaceutical Preparations, SIC 2834

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic conditions. The company primarily targets bitter taste receptors expressed in the gut lumen to stimulate the release of endogenous signaling molecules that help alleviate hunger. Its product candidates include ARD-101, an oral gut-restricted agonist under evaluation for hyperphagia associated with Prader-Willi Syndrome, and ARD-201, a combination therapy intended for obesity and weight regain prevention.

The company operates in the United States and has conducted clinical trial activities across several international jurisdictions, including Australia, the United Kingdom, South Korea, and Canada. Aardvark Therapeutics maintains its principal executive offices in San Diego, California. The company relies on third parties and clinical sites to support the ongoing development and evaluation of its investigational product candidates across these geographic regions.

Summary of the business section of Aardvark Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Aardvark Therapeutics, Inc.
Founded
2017
Headquarters
San Diego, CA
Address
4370 La Jolla Village Drive, Suite 1050 92122
Phone
(858) 225-7696
Employees
40, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C, San Diego, California

Stock & identifiers

Ticker
AARD
Exchange
Nasdaq
IPO date
Feb 13, 2025
Shares outstanding
22M, Jul 31, 2026
Public float
$162.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1774857
CUSIP
002942100
ISIN
US0029421007
FIGI
BBG01223DLB2
Share class FIGI
BBG01223DLC1
EIN
82-1606367

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Tien-Li LeeChief Executive Officer, Director3,025,641
Manasi JaimanChief Medical Officer–
Nelson SunSee Remarks35,475
Bryan JonesChief Operating Officer1,250
Zhongwei ZhangDirector–
Jeffrey ChiDirector133,364
Susan E. GrafDirector–
Roy D. BaynesDirector–
Victor Edward Tong JrDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payTotalvs. prior year
Tien-Li Lee, M.D.
Chief Executive Officer
$630.79K$5.09M$342.87K$6.07M+569%
Nelson Sun
Chief Financial Officer and Chief Operating Officer
$432.65K$1.94M$170.65K$2.55M–
Manasi Jaiman, M.D., M.P.H.
Chief Medical Officer
$495.96K$1.18M$197.08K$1.87M+130%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 13, 2025
Offer price
$16.00
Securities offered
5,888,000
Gross proceeds
$94.21M
Exchange
Nasdaq
Lock-up ends (est.)
Aug 12, 2025

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 28, 2026, we had 40 employees, all of whom were full-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?